{"id":"NCT00967018","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Long Term Safety Study of Degarelix in Patients With Prostate Cancer","officialTitle":"A Phase IIIb, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients With Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-11","completion":"2011-12","firstPosted":"2009-08-27","resultsPosted":"2012-12-24","lastUpdate":"2013-01-03"},"enrollment":77,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix","otherNames":[]}],"arms":[{"label":"Degarelix","type":"EXPERIMENTAL"}],"summary":"Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30 (NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of degarelix until the drug is launched in their country. Safety parameters such as electrocardiogram (ECG), blood and urine samples and general health state will be studied. Note: patients completing the CS27 trial did not participate in the CS34 trial.","primaryOutcome":{"measure":"Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables","timeFrame":"Up to 22.5 months","effectByArm":[{"arm":"Degarelix","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":62,"countries":["Belgium","France","Italy","Portugal","Spain","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":77},"commonTop":["Injection site inflammation","Influenza","Chills","Injection site pain","Musculoskeletal pain"]}}